Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

(2009) T. Arumugam et al.   CANCER RESEARCH

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug

(2009) Shu-Ping Wang et al.   NATURE CELL BIOLOGY

Personalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer

(2009) Adi F. Gazdar   NEW ENGLAND JOURNAL OF MEDICINE

The Malignant Pleural Effusion as a Model to Investigate Intratumoral Heterogeneity in Lung Cancer

(2009) Saroj K. Basak et al.   PLoS One

Slug (SNAI2) Down-Regulation by RNA Interference Facilitates Apoptosis and Inhibits Invasive Growth in Neuroblastoma Preclinical Models

(2008) R. Vitali et al.   CLINICAL CANCER RESEARCH

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

(2008) Jin Kyung Rho et al.   LUNG CANCER